Victory Capital Management
XFOR icon

Victory Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Victory Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-498
Closed -$9.99K – 2542
2024
Q3 		$9.99K Sell
498
-9
-2% -$188 ﹤0.01% 2474
2024
Q2 		$8.82K Sell
507
-25
-5% -$818 ﹤0.01% 2470
2024
Q1 		$22.2K Sell
532
-37
-7% -$1.03K ﹤0.01% 2440
2023
Q4 		$14.3K Buy
569
+111
+24% +$2.7K ﹤0.01% 2521
2023
Q3 		$15K Buy
458
+78
+21% +$3.4K ﹤0.01% 2465
2023
Q2 		$22.1K Buy
+380
New +$19.5K ﹤0.01% 2442
2020
Q2 		– Sell
-78
Closed -$23K – 3305
2020
Q1 		$23K Buy
+78
New +$22.1K ﹤0.01% 2799
2019
Q4 		– Sell
-66
Closed -$25K – 3299
2019
Q3 		$25K Buy
+66
New +$26.1K ﹤0.01% 2966

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Victory Capital Management's XFOR Position: Q4 2024 in Review

Victory Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 498 shares — an estimated $9.99K sold.

Victory Capital Management first reported a position in XFOR in Q3 2019 and held it in 8 quarters. The position peaked at $25K in Q3 2019. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Victory Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Victory Capital Management sold 498 X4 Pharmaceuticals shares in Q4 2024, an estimated $9.99K.
  • Victory Capital Management first reported a position in X4 Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Victory Capital Management's X4 Pharmaceuticals position peaked at $25K in Q3 2019.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Victory Capital Management's 13F filing for Q4 2024, filed 6 Feb 2025.